about
Biomarkers of residual disease, disseminated tumor cells, and metastases in the MMTV-PyMT breast cancer modelK-ras mutational status in cytohistological tissue as a molecular marker for the diagnosis of pancreatic cancer: a systematic review and meta-analysisExpression of stem cell and epithelial-mesenchymal transition markers in circulating tumor cells of breast cancer patientsGoblet cell carcinoids of the appendixCancer risk assessment, indicators, and guidelines for polycyclic aromatic hydrocarbons in the ambient airThe ring-type polymerase sliding clamp familyCurrent status of biomarkers for prostate cancerImproved endpoints for cancer immunotherapy trialsSporadic haemangioblastoma of the kidney with rhabdoid features and focal CD10 expression: report of a case and literature reviewMUC1: a multifunctional cell surface component of reproductive tissue epitheliaThe diagnosis of BCR/ABL-negative chronic myeloproliferative diseases (CMPD): a comprehensive approach based on morphology, cytogenetics, and molecular markersSteroid receptor RNA activator (SRA1): unusual bifaceted gene products with suspected relevance to breast cancerPrognostic molecular markers in early breast cancerGenetic abnormalities in pancreatic cancerMolecular biology of breast cancer metastasis. Molecular expression of vascular markers by aggressive breast cancer cells.Prostate-specific antigen (PSA/hK3): a further player in the field of breast cancer diagnostics?Predictive factor for the response to adjuvant therapy with emphasis in breast cancer.Update on HER-2 as a target for cancer therapy: herceptin in the clinical setting.Update on HER-2 as a target for cancer therapy: the ERBB2 promoter and its exploitation for cancer treatmentUpdate on HER-2 as a target for cancer therapy: HER2/neu peptides as tumour vaccines for T cell recognition.A new model for ductal carcinoma in situ suggests strategies for treatmentTyrosine kinase signalling in breast cancer: ErbB family receptor tyrosine kinasesProteomic-Based Approaches for the Study of Cytokines in Lung CancerPredictive Biomarkers in Colorectal Cancer: From the Single Therapeutic Target to a Plethora of OptionsFunctional Consequences of Differential O-glycosylation of MUC1, MUC4, and MUC16 (Downstream Effects on Signaling)Liquid Biopsy of Hepatocellular Carcinoma: Circulating Tumor-Derived BiomarkersTyrosine Kinase Receptor Landscape in Lung Cancer: Therapeutical ImplicationsCirculating Tumor Cells in the Adenocarcinoma of the EsophagusTechnical challenges in the isolation and analysis of circulating tumor cellsNon-Invasive Methods to Monitor Mechanisms of Resistance to Tyrosine Kinase Inhibitors in Non-Small-Cell Lung Cancer: Where Do We Stand?Gastric biomarkers: a global reviewCan we use methylation markers as diagnostic and prognostic indicators for bladder cancer?Current status and perspectives in translational biomarker research for PD-1/PD-L1 immune checkpoint blockade therapyLong noncoding RNAs in cancer: mechanisms of action and technological advancementsCirculating MicroRNAs as Biomarkers in Biliary Tract CancersCirculating tumor DNA: a promising biomarker in the liquid biopsy of cancerFirst-line therapy in HER2 positive metastatic breast cancer: is the mosaic fully completed or are we missing additional pieces?Long noncoding RNAs as novel predictors of survival in human cancer: a systematic review and meta-analysismiR-155 as a Biomarker in B-Cell MalignanciesCancer stem cells (CSCs), cervical CSCs and targeted therapies
P921
Q21090788-335CCE9F-4B36-4538-A5AA-8E1328E0E29CQ21284688-82D034C0-086A-4D99-96CC-2C3AAF81F357Q21284707-6682F518-3252-47BA-BF6C-6B62C4FA269AQ21284834-977E7048-4456-490A-8032-50AA95032EEAQ24529932-EC45A3AA-A299-4ED3-A732-AA4E0D8714C2Q24551008-228FDE11-AA1F-4F92-8959-740A106DF1A5Q24600574-7DC1BB04-213A-409A-81C7-82929DDE6D4AQ24603112-6D21A7F1-5A42-4C4A-A1E4-F03C25D50862Q24615724-F8ECE7B3-96C5-48F0-A5AC-FFB036C8DEBEQ24633038-6B72FB87-77BE-46D2-A785-03FAE993F1C2Q24675681-E489D294-B10A-4D5C-859D-6F344BDED7FBQ24680310-4D58437E-C7F8-4749-A407-3368EFD16B2BQ24794845-06732FC1-FF8D-4385-9CEF-E97E6C27CAE8Q24800194-E019BE99-48EA-4AD0-B1EC-46CA67FE954EQ24800983-5C3EA267-BCDC-47F6-B09B-DA48CF105DD2Q24801573-333F459B-166E-4157-874A-D2B56759131AQ24801874-18914574-895A-44B4-8304-CF67533100DEQ24801924-7CD065AC-4207-45FA-840C-06BA8E958684Q24801967-723D8DD6-33EC-4EF6-9C64-5F989DCF9C1DQ24801995-B2304124-9A54-455C-B214-DEAEFAC07D88Q24802734-C1006B1B-6940-453E-B576-B39671E6B909Q24802950-34545A96-9354-4412-A690-4FEDEF5B711FQ26738539-DBA8CC07-48B9-4151-8D08-44AE32B71F6EQ26738655-78D2A878-0B80-4391-A407-A829E60919DDQ26739942-1197BAE4-03F9-4567-A7B7-38D1CC526358Q26741204-5EF26EBB-86CA-4F9C-851E-3AADAD1DB0EDQ26741318-39483317-C9C8-4001-942D-7AEB58D94075Q26741429-A8777507-D598-4BF1-B4B6-8BD8B63ED5A5Q26741646-FC41B564-80B2-4B67-A677-3432F10D631AQ26741814-6B50C33C-F3D4-457B-84E3-6156C67BB855Q26741859-E4092E39-0F31-42DB-916E-5349E9EAFFCDQ26744146-22626AF4-3EC0-4791-B2FF-88567A3653C2Q26745516-7BE304B6-6003-4AAF-B832-453B0A869C03Q26745528-0751CD90-B97A-4E91-9703-5EB0F42F2869Q26746000-49AC183A-4FE5-44FA-B2C8-75F18035796BQ26746010-276960F8-7DB7-4DA0-8C00-E2B782C403E5Q26746081-D602FE15-0BB0-4F20-8B40-9B823EC36638Q26746258-23B97146-CC0E-4798-A81C-54F6859496C9Q26746573-562B2B03-C804-4C79-9DCB-16326B99D7AAQ26747144-127155D2-8E4E-440D-8FC4-213389100136
P921
description
products metabolized and secre ...... ically in cells or body fluids
@en
name
tumor biomarkers
@en
type
label
tumor biomarkers
@en
altLabel
Biomarkers, Tumor
@en
tumor biomarker
@en
prefLabel
tumor biomarkers
@en
P486
P672
P279
P486
P672
D23.101.140